CYP2D6 Genotyping and Inhibition as Predictors of Adverse Drug Reactions in Depressive Disorders

References (43)

1. Depression and Other Common Mental Disorders: Global Health Estimates. World Health Organization. Licence: CC BY-NC-SA 3.0 IGO; 2017. https://www.who.int/publications/i/item/depression-global-health-estimates/
2. Brody DJ, Gu Q. Antidepressant use among adults: United States, 2015-2018. NCHS Data Brief. 2020;(377):1–8. PubMed
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. PubMed CrossRef
4. Gyllensten H, Rehnberg C, Jönsson AK, et al. Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey. BMJ Open. 2013;3(6):e002574. PubMed CrossRef
5. Solomon HV, Cates KW, Li KJ. Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions? Psychiatry Res. 2019;271:604–613. PubMed CrossRef
6. Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1-02):e1. PubMed CrossRef
7. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116(3):496–526. PubMed CrossRef
8. Pharmacogene Variation Consortium (PharmVar). Updated December 20, 2022. Accessed Jan 20, 2023. www.PharmVar.org/genes
9. Gaedigk A, Casey ST, Whirl-Carrillo M, et al; Pharmacogene Variation Consortium. Pharmacogene Variation Consortium: a global resource and repository for pharmacogene variation. Clin Pharmacol Ther. 2021;110(3):542–545. PubMed CrossRef
10. Gaedigk A, Ingelman-Sundberg M, Miller NA, et al; PharmVar Steering Committee. The Pharmacogene Variation (PharmVar) consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther. 2018;103(3):399–401. PubMed CrossRef
11. Gaedigk A, Whirl-Carrillo M, Pratt VM, et al. PharmVar and the landscape of pharmacogenetic resources. Clin Pharmacol Ther. 2020;107(1):43–46. PubMed CrossRef
12. Altar CA, Hornberger J, Shewade A, et al. Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. Int Rev Psychiatry. 2013;25(5):509–533. PubMed CrossRef
13. Shah RR, Smith RL. Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br J Clin Pharmacol. 2015;79(2):222–240. PubMed CrossRef
14. Asp M, Lindqvist D, Fernström J, et al. Recognition of personality disorder and anxiety disorder comorbidity in patients treated for depression in secondary psychiatric care. PLoS One. 2020;15(1):e0227364. PubMed CrossRef
15. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22–33, quiz 34–57. PubMed
16. First M, Gibbon M, Spitzer RL, et al. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). American Psychiatric Press, Inc; 1997.
17. Åsberg M, Montgomery SA, Perris C, et al. A comprehensive psychopathological rating scale. Acta Psychiatr Scand suppl. 1978;57(S271):5–27. PubMed CrossRef
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. American Psychiatric Association; 2000.
19. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389. PubMed CrossRef
20. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale:  new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand suppl. 1987;76(s334):1–100. PubMed CrossRef
21. Lindström E, Lewander T, Malm U, et al. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia: clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry. 2001;55(suppl 44):5–69. PubMed CrossRef
22. Söderbäck E, Zackrisson AL, Lindblom B, et al. Determination of CYP2D6 gene copy number by pyrosequencing. Clin Chem. 2005;51(3):522–531. PubMed CrossRef
23. Zackrisson AL, Lindblom B. Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing. Eur J Clin Pharmacol. 2003;59(7):521–526. PubMed CrossRef
24. Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13(1):116–124. PubMed CrossRef
25. Pharm GKB. Accessed Nov 1, 2022. https://www.PharmGKB.org/
26. Whirl-Carrillo M, Huddart R, Gong L, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110(3):563–572. PubMed CrossRef
27. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417. PubMed CrossRef
28. Flockhart DA, McDonald C, Desta Z. The Flockhart Cytochrome P450 Drug-Drug Interaction Table. Division of Clinical Pharmacology, Indiana University School of Medicine. Updated 2021. Accessed Aug 27, 2023. https://drug-interactions.medicine.iu.edu
29. Borges S, Desta Z, Jin Y, et al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol. 2010;50(4):450–458. PubMed CrossRef
30. Walden LM, Brandl EJ, Tiwari AK, et al. Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication. Psychiatry Res. 2019;279:111–115. PubMed CrossRef
31. Ng C, Sarris J, Singh A, et al. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Hum Psychopharmacol. 2013;28(5):516–522. PubMed CrossRef
32. Roberts RL, Mulder RT, Joyce PR, et al. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol. 2004;19(1):17–23. PubMed CrossRef
33. Hodgson K, Tansey KE, Uher R, et al. Exploring the role of drug-metabolising enzymes in antidepressant side effects. Psychopharmacology (Berl). 2015;232(14):2609–2617. PubMed CrossRef
34. Steimer W, Zöpf K, von Amelunxen S, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem. 2005;51(2):376–385. PubMed CrossRef
35. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther. 2004;75(5):386–393. PubMed CrossRef
36. Sánchez-Iglesias S, García-Solaesa V, García-Berrocal B, et al. Role of pharmacogenetics in improving the safety of psychiatric care by predicting the potential risks of mania in CYP2D6 poor metabolizers diagnosed with bipolar disorder. Medicine (Baltimore). 2016;95(6):e2473. PubMed CrossRef
37. Preskorn SH, Kane CP, Lobello K, et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry. 2013;74(6):614–621. PubMed CrossRef
38. Storelli F, Matthey A, Lenglet S, et al. Impact of CYP2D6 functional allelic variations on phenoconversion and drug-drug interactions. Clin Pharmacol Ther. 2018;104(1):148–157. PubMed CrossRef
39. Funk CSM, Hart XM, Gründer G, et al. Is therapeutic drug monitoring relevant for antidepressant drug therapy? implications from a systematic review and meta-analysis with focus on moderating factors. Front Psychiatry. 2022;13:826138. PubMed CrossRef
40. Uher R, Farmer A, Henigsberg N, et al. Adverse reactions to antidepressants. Br J Psychiatry. 2009;195(3):202–210. PubMed CrossRef
41. Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32. PubMed CrossRef
42. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, et al. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19(1):69–76. PubMed CrossRef
43. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102(4):688–700. PubMed CrossRef